Loading
Breakthru Medicine is a Phoenix cancer drug company working on small molecules, a molecular glue platform and new drug payloads for antibody-drug conjugates. It came out of stealth in January 2026 and aims to start its first clinical trial in early 2027.
Breakthru Medicine, based in Phoenix, Arizona, emerged from stealth on 29 January 2026 with a USD 60 million Series A, following an undisclosed seed round. It describes a patient-first, tumour-agnostic targeting approach across multiple modalities, including small molecules, next-generation antibody-drug conjugate payloads and an emerging molecular glue platform whose details it has not disclosed. The company was founded by Steve Potts (chief executive), Mark Mulvihill (chief scientific officer) and Brian Barnett; its board and investors include Dave Morehead, Fred Eshelman of Eshelman Ventures, and Mark Gergen. Its website states that its lead programme is targeting clinical trials in early 2027.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series A · Followed an undisclosed seed round | 2026 | $60M | breakthrumed.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation).
Shares Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation).
Shares Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation).
Shares Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation).
Shares Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation).
Shares Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation).
Shares Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation).
Shares Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/